Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management

Cited by (508)

Items 101–200 of 508

1. Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management
   Yi Gao, Di Zhou, Xue Fei Bai, Yunjie Wang, Chenchen Wang, Lintao Bi · 2025 · Frontiers in Pharmacology
2. Advances in multiple myeloma blood-based monitoring and its clinical applications
   Anastasia Tzasta, Charissa Wijnands, Kim Baalman, Alain J. van Gool, Sonja Zweegman, Joannes F.M. Jacobs · 2025 · Critical Reviews in Clinical Laboratory Sciences
3. Discovery of Potential GPRC5D Inhibitors through Virtual Screening and Molecular Dynamics Simulations
   Xi Chen, Xinle Yang, Roufen Chen, Lei Xu, Xiaowu Dong, Zhen Cai · 2025 · ChemistryOpen
4. Epidemiological Trends and Disease Burden of Multiple Myeloma in the Middle-Aged and Elderly Population: A Global Study from 1990 to 2021
   Yuecan Chen, Yanjie Jiang, Yehan Xu, Yucao Ma, Wenjing Yao, Haosen Wang, Yiheng Lu, Qinhan Cao, Xin Zhang, Liyuan Peng et al. · 2025 · Cancer Investigation
5. Extended verification of an automated MALDI-TOF mass spectrometry system for high throughput serum M-protein measurement
   Louis Nevejan, Jan Van Droogenbroeck, Emile Van Hecke · 2025 · Clinical Chemistry and Laboratory Medicine (CCLM)
6. Validation of the new IMS/IMWG consensus genomic staging (CGS) of high‐risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients
   Efstathios Kastritis, Charalampos Filippatos, Maria Gavriatopoulou et al. · 2025 · HemaSphere
7. Multiplexed Imaging Reveals Immune-Metabolic Niches in Multiple Myeloma Linked to Progression and Bone Disease
   Ingrid Aass Roseth, Lukas Hatscher, C. Schiller, Håkon Skjalg Selland Johnstuen, Tobias Schmidt Slørdahl, Håkon Hov, Denis Schapiro, Therese Standal · 2026 · Blood Cancer Discovery
8. Harmonizing M-protein analysis: an international, multi-center reproducibility study of mass spectrometry and evaluation of concordance to electrophoretic methods
   Katie L. Thoren, Lauren Campbell, Rosa Pello · 2026 · Clinical Chemistry and Laboratory Medicine (CCLM)
9. Melflufen in Multiple Myeloma: Clinical Limitations, Biological Rationale, and Future Perspectives
   Matteo Garibotto, Debora Soncini, Roberto Massimo Lemoli · 2026 · Cancers
10. Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab
    Ziping Li, Fujing Zhang, Xianghong Jin, Junling Zhuang · 2025 · Journal of Translational Medicine
11. Long-term trends in the burden of multiple myeloma in China: a Joinpoint regression and age-period-cohort analysis based on GBD 2021
    Yanyu Zhang, Qing Su, Jiawen Yu · 2025 · Frontiers in Public Health
12. Recombinant human thrombopoietin does not promote platelet engraftment in newly diagnosed multiple myeloma patients following autologous stem cell transplantation
    Ruiqi Wang, Jing Cai, Ziqi Chen, Hao Tian, Dan Cong, Yuansong Bai, Wenlong Zhang · 2025 · Scientific Reports
13. Psychometric Evaluation of the Chinese Version of the Quality-of-Life Questionnaire for Patients with Multiple Myeloma
    Chao Liu, Li Wang, Yin Wu · 2025 · Palliative Medicine Reports
14. Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point?
    María‐Victoria Mateos, Noemí Puig · 2025 · Journal of Clinical Oncology
15. The Spinal Bone Marrow in Health and Disease
    Wende N. Gibbs · 2025 · Magnetic Resonance Imaging Clinics of North America
16. Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients
    Fortunato Morabito, Enrica Antonia Martino, Mónica Galli et al. · 2025 · European Journal Of Haematology
17. Functional Cure as a New Concept of Therapy for Multiple Myeloma
    С. В. Семочкин · 2025 · Clinical oncohematology
18. Adherence to Multidisciplinary Tumor Board Recommendations in Patients with Multiple Myeloma
    Valérie Gennheimer, Dilara Akhoundova, Michèle Hoffmann · 2025 · Cancers
19. Definition, Diagnosis, Risk Stratification and Management of Newly Diagnosed Multiple Myeloma: The Saudi Myeloma Working Group Guidelines
    Ghazi Alotaibi, Abdullah S. Al Saleh, Ayman Alhejazi, Majed D. Alahmadi, Ibraheem Motabi, Fahad Z. Alsharif, Abdullah Alamer, Omar Abduljalil, Imran Khan Tailor, Mohammed A. Marei et al. · 2025 · Clinical Lymphoma Myeloma & Leukemia
20. MASS-4 is more suitable than MASS-3 for prognostic stratification in transplant-eligible patients with newly diagnosed multiple myeloma
    Fan Yang, Junru Liu, Jingli Gu, Meilan Chen, Beihui Huang, Lifen Kuang, Juan Li · 2025 · Annals of Medicine
21. Hematological malignancy burden in mainland China and Taiwan from 1990 to 2021 and decadal projections: Insights from the global burden of disease study 2021
    Yu Fu, Yazhe Du, Yun-Wei Zhang, Fei Song, Sujun Gao, Long Su · 2025 · PLoS ONE
22. Advances in RNA therapeutics and its delivery strategies against Multiple Myeloma
    Kaiwen Luo, Zhongkun Zhang, Siyu Yao, Yufei Wang, Mansoor M. Amiji, Kenneth Carl Anderson · 2025 · Journal of Controlled Release
23. CD24 expression for better outcome prediction in newly diagnosed multiple myeloma patients
    Lu Wang, Hui Geng, Jie Ma, Youliang Li, Qichao Yin, Yan Jiang · 2025 · Medicine
24. Targeting sex-specific DRG inflammation and neurofibrosis to prevent Bortezomib-induced neuropathy
    Michael B Thomsen, Abhishek Gajendra Singh, Christina N. Thebeau, Vivian D. Gao, Nicholas F. Schulze, Shannon M. Landon, Oshri Avraham, Sarah X. Yang, Shriya Koneru, Sami S. Geier et al. · 2025 · Brain Behavior and Immunity
25. Deep learning and transformer-based feature fusion of conventional MRI for differentiating spinal osteolytic bone metastases and multiple myeloma
    Haicheng Bian, Na Tian, Yuzhu Zhang · 2025 · European Journal of Radiology
26. Cardiovascular complications and their association with short‐ and long‐term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T‐cell therapy
    Osnat Itzhaki Ben Zadok, Panagiotis Simitsis, Caron Alyce Jacobson, Omar Nadeem, Matthew J. Frigault, Noopur S Raje, Caitlyn Duffy, Patrick Costello, Jamie Dela Cruz, Andrew Looka et al. · 2025 · British Journal of Haematology
27. The prognostic value of POD24 for multiple myeloma: a comprehensive analysis based on traditional statistics and machine learning
    Quane Zhang, Yifan Wang, Qiuni Chen et al. · 2025 · BMC Cancer
28. Functional role of granulocytic myeloid-derived suppressor cells in CAR-T therapy: insights from single-cell RNA sequencing in multiple myeloma
    Chao Zhang, Fang An · 2025 · Immunopharmacology and Immunotoxicology
29. CD38-specific nanobody-based bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells
    Luca Julius Pape, Anna Josephine Gebhardt, Marten Dannenberg, Henry Risch, Anya Duttmann, Katja Christina Weisel, Julia Hambach, Friedrich Koch‐Nolte, Peter Bannas · 2025 · Scientific Reports
30. Burden of Treatment, Treatment Sequencing and Healthcare Resource Utilization in Multiple Myeloma in Latin America: A Targeted Literature Review
    Cristian Maximiliano Seehaus, Guillermina Remaggi, Jayr Schmidt Filho · 2025 · Oncology and Therapy
31. Extracellular vesicles in multiple myeloma-bone marrow niche crosstalk: from cellular dialogue to clinical perspectives
    Martina Forestiero, Anna Maria Zimbo, Giulia Gentile, Marianna Puzzo, Rocco Malivindi, Enrica Antonia Martino, Ernesto Vigna, Massimo Gentile, Daniela Bonofiglio, Luca Gelsomino et al. · 2025 · Journal of Translational Medicine
32. Peripheral Neuropathy Associated With Proteasome Inhibitors and Immunomodulatory Drugs: A Pharmacovigilance Disproportionality Analysis Using VigiBase
    Letícia Penna Braga, Cristiane Aparecida Menezes de Pádua, Iwyson Henrique Fernandes da Costa, Paula Lana de Miranda Drummond, Pedro Henrique Carvalho de Souza, Laura Beatriz Fonseca, Marina Alacoque, Jéssica Soares Malta, Adriano Max Moreira Reis · 2025 · Pharmacology Research & Perspectives
33. Plasma Cell Myeloma: Biochemical Insights into Diagnosis, Treatment, and Smart Nanocarrier-Based Therapeutic Development
    Lizeth Geraldine Muñoz, Sixta Palencia Luna, Andrés Felipe Chamorro · 2025 · Pharmaceutics
34. Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis
    João Tadeu Damian Souto Filho, Lucas Oliveira Cantadori, Edvan de Queiroz Crusoé, Vânia Hungria, Ângelo Maiolino · 2025 · Blood Cancer Journal
35. Complementary Roles of Next-Generation Flow and Next-Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma
    Min-Seung Park, Dae Jin Lim, Hee-Jin Kim · 2025 · Journal of Korean Medical Science
36. The importance of autophagy in multiple myeloma
    Martyna Bednarczyk, Nicola Szeja, Dariusz Łętowski, Anna Kozub, Aleksandra Nasiek, Sebastian Grosicki · 2025 · Expert Review of Anticancer Therapy
37. Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)( CCND1 ; IGH )
    Marcella Kaddoura, Julia Erin Wiedmeier, Vikas Anand Gupta, Tomas Jelinek, Bachisio Ziccheddu, Suganti Shivaram, Hongwei Tang, Rebecca W Owens, Tereza Sevcikova, Rodrigo Fonseca et al. · 2026 · Blood
38. Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review
    Karun Neupane, Mitch Singstock, Darshi Shah, Riyasha Dahal, Hira S. Mian, Febe Smith, Rajshekhar Chakraborty, Samer S.A. Al Hadidi, Maria Mainou, Ariel Felipe Grajales-Cruz et al. · 2026 · British Journal of Haematology
39. Linvoseltamab, a BCMA-directed CD3 T-cell engager for multiple myeloma: a patient-centric option via a response-adapted dosing regimen
    Jacob Alexander Lowy, Michael F. Rogers, Zachary M. Avigan, Marcus S. Flores, Marina Samuel, Mohammad A. Rattu, Joshua Richter · 2026 · Expert Review of Hematology
40. The role of antioxidants in multiple myeloma: diagnostic, prognostic, and therapeutic applications: a narrative review
    Sintayehu Admas, Bisrat Birke Teketelew, Nigusie Alemu, Lyusira Marelgn, Yemataw Gelaw · 2026 · Therapeutic Advances in Hematology
41. Serum free light chain concentration and ratio‐based criterion for myeloma‐defining event, in its current version, is untenable
    Gurmukh Singh · 2026 · British Journal of Haematology
42. Artificial intelligence reshaping the paradigm of hematologic malignancy diagnosis and treatment: From static assessment to dynamic precision management
    Zhujin Li, Jie Zhao, Lifang Huang, Xiuhua Chen, Jia Wei, Weiwei Tian · 2026 · Annals of Hematology
43. Plasmablastic multiple myeloma presenting as a pleural mass: a diagnostic challenge
    Maciej Kabat, Vanisha Patel, Pritish K. Bhattacharyya · 2024 · BMJ Case Reports
44. Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study Group
    Eirini Katodritou, Efstathios Kastritis, Dimitra Dalampira, Despina Fotiou, Fotini Theodorakakou, Sosana Delimpasi, Emmanouil Spanoudakis, Ioannis Ntanasis‐Stathopoulos, Theodosia Papadopoulou, Aggeliki Sevastoudi et al. · 2025 · Clinical Lymphoma Myeloma & Leukemia
45. Targeting the HuR/E2F7 axis synergizes with bortezomib against multiple myeloma
    Min Jia, Chao Wu, Ze Fu, Wenbin Xu, Jia Liu, Chengyu Wu, Xin-yi Zeng, Yingli Wu, Hua Yan · 2025 · Acta Pharmacologica Sinica
46. Single-Nucleotide Polymorphisms Related to Multiple Myeloma Risk: A Systematic Review and Meta-Analysis
    Giovanna Gilioli da Costa Nunes, Francisco Cézar Aquino de Moraes, Aline Beatriz Carvalho de Almeida · 2025 · International Journal of Molecular Sciences
47. Trends and projections of the global and regional burden of multiple myeloma in adults aged 40 and over, 1990–2044
    Xi Liu, Haihui Zhuang, Fenglin Li · 2025 · Scientific Reports
48. Deep-Learning-Based Prediction of t(11;14) in Multiple Myeloma H&E-Stained Samples
    Nadav Kerner, Dov Hershkovitz, Svetlana Trestman, Tamir Shragai, Hila Ledermann Nahmias, Yael Chava Cohen, Tomer Ziv‐Baran, Irit Mazza Avivi · 2025 · Cancers
49. Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home
    Flavia Bigi, Mauro Fiacchini, Roberta Restuccia et al. · 2025 · Clinical and Experimental Medicine
50. DNA damage repair (DDR) related prognostic risk model in multiple myeloma based on single-cell and bulk sequencing
    Hongxiu Liu, Zhihua Li, Yihua Wang, Can Li, Kaiqing Yan, Yanping Ma · 2025 · DNA repair
51. Efficacy and safety of thalidomide for oncology-related uses approved in Brazil: An overview of systematic reviews
    Paula Lana de Miranda Drummond, Cristine de Araújo Silva, Júlia Estevão de Souza · 2025 · Journal of Oncology Pharmacy Practice
52. Medication-Related osteonecrosis of the jaw involving dental implants: A 16-Year observational study in a single cancer center
    RAPHAEL DE LIMA CHAPARIN, Yuri de Lima Medeiros, Rui Figueiredo · 2025 · Clinical Oral Investigations
53. Daratumumab in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
    Chi Wang, Zhengyang Xu, Meilin Jiang, Yuzhe Chen, Lan Yu · 2025 · Cancers
54. Skeletal health in the precursor stages of multiple myeloma: fracture risk and bone phenotypes in monoclonal gammopathy of undetermined significance and smouldering myeloma
    Melissa D. Cantley, Laura J. Trainor, Emma A-J. Cheney, Suzanne M. Watt, Kate Vandyke · 2025 · Pathology
55. Outcomes of Double-Hit and Single High Risk Cytogenetic Newly Diagnosed Myeloma in Transplant Eligible Patients
    Raeef Labib Rahman, Anas Zayad, Carmel Awadallah et al. · 2024 · Blood
56. Macrophage depletion restores the DRG microenvironment and prevents axon degeneration in bortezomib-induced neuropathy
    Michael B Thomsen, Abhishek Gajendra Singh, Christina N. Thebeau, Vivian D. Gao, Nicholas F. Schulze, Oshri Avraham, Sarah X. Yang, Shriya Koneru, Sami S. Geier, Shannon M. Landon et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
57. Belantamab Mafodotin Triggers Immune Invigoration in Multiple Myeloma Via Inflammatory and Immunogenic Cell Death
    Edmund C. R. Watson, Halima Ali Shuwa, Morgan W. D. Heycock et al. · 2025 · medRxiv
58. The prognostic impact of 1q21 gain/amplification in newly diagnosed multiple myeloma: a retrospective study based on a single center in China
    Ye Li, Jingjing Deng, Wen-Ming Chen · 2025 · Annals of Hematology
59. Unmasking Multiple Myeloma: The Importance of Suspecting Malignancy in Atypical Chronic Pain Mimicking Degenerative Conditions—A Case Report
    Bi Mo, Sandra Sacks, Jerry Markar · 2025 · Clinical Case Reports
60. Efficacy of maintenance or consolidation therapy for multiple myeloma based on proteasome inhibitors: a meta-analysis
    Dan Wu, Feiqing Wang, Xu Yang et al. · 2025 · Discover Oncology
61. Autologous stem cell transplantation in multiple myeloma at Chris Hani Baragwanath Academic Hospital
    Vedanand Rawoo, Moosa Patel, Atul Lakha, Vinitha Philip, Muhammed Faadil Waja · 2025 · South African Journal of Oncology
62. One for the ages: impact of age on international prognostic indices in lymphoid cancer
    Christian Brieghel, Emelie Curovic Rotbain, Jelena Jelicic · 2025 · Blood Advances
63. Therapeutic Potential of Venetoclax and Selinexor in Targeting Hypoxia‐Induced Vulnerabilities in Multiple Myeloma
    Seiichi Okabe, Yuya Arai, Yuko Tanaka · 2025 · Cancer Reports
64. Peripheral blood CD4+CD25+ T lymphocytes and TGF-β predict the prognosis in relapsed/refractory multiple myeloma treated with daratumumab
    Hanyue Xue, Wei Fang, Ruiyang Li · 2025 · Seminars in Oncology
65. A comparison of cyclophosphamide at different dose levels for stem cell mobilization in multiple myeloma
    Abdullah Karakuş, Ugur Hatipoglu, Yavuz Katırcılar et al. · 2025 · Transfusion and Apheresis Science
66. Real-World Practice in the Management of Transplant-Eligible Newly Diagnosed Multiple Myeloma: A US-Based Cross-Sectional National Survey
    Hossam M. Ali, Zainab Yusufali Motiwala, Yara Shatnawi, Jack Khouri, Faiz Anwer, Hussein Awada, Anam Ashfaque, Danai Dima, Louis S. Williams, Nausheen Ahmed et al. · 2025 · Clinical Lymphoma Myeloma & Leukemia
67. Performance and comparison of FLCCheck: a novel serum free light chain assay for the Auxiliary Diagnosis of Multiple Myeloma
    Jie Cao, Xi Chen, Yu Jerry Zhou, Yajuan Lu, Aoli Deng, Sainan Li, Yuhan Chen, Jing Du, Jun Xia · 2025 · European journal of medical research
68. Prospective comparison between geriatric assessment and clinical evaluation in 200 newly diagnosed older adults with multiple myeloma
    Jolien Raddoux, Cindy Kenis, Anneleen Vanhellemont, Stef Meers, Philippe Mineur, Marie‐Christiane Vekemans, Ka Lung Wu, Jo Caers, Koen Van Eygen, Alain Kentos et al. · 2025 · Journal of Geriatric Oncology
69. Comparison of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Primary Plasma Cell Leukemia in Japan
    Masaya Maegaki, Tsutomu Takahashi, Kazuhito Suzuki et al. · 2025 · Transplantation and Cellular Therapy
70. Tandem autologous hematopoietic stem cell transplantation in multiple myeloma: A historical perspective and current challenges
    Xueting Wang, Yushan Cui, Yaomei Wang, Baijun Fang · 2025 · Annals of Hematology
71. Modified Glasgow Prognostic Score Incorporating CRP/Albumin Ratio and LDH Levels as Prognostic Indicators in Patients with Multiple Myeloma: A Retrospective Study
    Mustafa Duran, Nermin Keni Beğendi · 2025 · Cancer Management and Research
72. Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma
    Santosh Gautam, Laura Morrison, Philippe Thompson‐Leduc · 2025 · Journal of Managed Care & Specialty Pharmacy
73. Is it Necessary to Achieve a Very Good Partial Response Prior to Transplant? Comparison of Outcomes in Pre-Transplant Partial Response Versus Very Good Partial Response or Deeper
    Sumeet Prakash Mirgh, Jyotsna Kapoor, Niharika Bhatia et al. · 2025 · Indian Journal of Hematology and Blood Transfusion
74. Discovery and Characterization of Novel PIM1 Inhibitors via Virtual Screening and Molecular Dynamics Simulations
    Yan Lu, Yan Lu, Yingxuan Xu · 2025 · ACS Medicinal Chemistry Letters
75. Predictors of quality of life in multiple myeloma patients: a multi-centered cross-sectional study
    Nizar Abu Hamdeh, Mohammad Alnees, Osama Ewidat et al. · 2025 · BMC Cancer
76. CAR-T cell therapy for multiple myeloma: An update on the current state and future potential
    Prateek A. Pophali, Jacalyn M. Rosenblatt, David Avigan · 2025 · Best Practice & Research Clinical Haematology
77. Combining IMWG GA and hematopoietic score to optimize the evaluation of dynamic chemotherapy tolerance in multiple myeloma
    Yadong Chen, Fenfen He, Yanyu Chen · 2025 · Annals of Medicine
78. Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment response
    Anna Maria Corsale, Mojtaba Shekarkar Azgomi, Emilia Gigliotta et al. · 2025 · Blood Neoplasia
79. Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial
    Ishita Kamboj, Alma Habib, Darryl Chang, Aliya Rashid, Andrew J. Vegel, Kevin Graf, Emily Struble, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Kimberly Green et al. · 2025 · Clinical Lymphoma Myeloma & Leukemia
80. Efficacy and Safety of Isatuximab Combination Therapy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
    Chi Wang, Zhengyang Xu, Meilin Jiang, Yuzhe Chen, Yu Lan · 2025 · Cancers
81. The role of the bone marrow microenvironment in disease progression and drug resistance in multiple myeloma in the era of novel agents
    Ludovica Guadagno, Jaqueline Schütt, Kerstin Brinkert, Tino Schenk, Annamaria Brioli · 2025 · Leukemia & lymphoma/Leukemia and lymphoma
82. Cytomegalovirus reactivation with severe lymphopenia during elranatamab treatment: a case series in patients with triple-class refractory multiple myeloma
    Aika Kitamura, Shinya Fujita, Yuki Isono, Tomoka Nakano, Takumi Morino, Kiho Tozuka, Himari Kudo, Ryohei Abe, Sumiko Kohashi, Takaaki Toyama · 2025 · Journal of Infection and Chemotherapy
83. Adipokines as Prognostic Biomarkers in Multiple Myeloma: A Case–Control Study
    Nóra Obajed Al-Ali, Dóra Csige, László Imre Pinczés, Katalin Farkas, István Rebenku, Andrea Domján, György Panyi, Zoltán Szekanecz, Gabriella Szűcs, Árpád Illés et al. · 2025 · Medicina
84. Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma
    Oren Pasvolsky, Curtis Marcoux, Denái R. Milton, Asad A. Haider, Mark R. Tanner, Qaiser Bashir, Samer Ali Srour, Neeraj Y. Saini, Portia Smallbone, Paul Lin et al. · 2025 · Bone Marrow Transplantation
85. BioMarrow: An accessible and reproducible 3D patient-derived bone marrow model for advancing research and clinical applications
    Diana Lourenço, Raquel Lopes, Joana Caetano · 2025 · Translational Oncology
86. Selinexor-loaded polymeric micelle for multiple myeloma therapy
    Peipei Yang, Ying Qu, Bingyang Chu et al. · 2025 · Chinese Chemical Letters
87. A Bird’s Eye View: A Close Look into Avian CAM Models for Translational Blood Cancer Research
    Izabela Cymer, Niamh McAuley, Cathy E. Richards, Hanne Jahns, Siobhan V. Glavey, Ann M. Hopkins · 2026 · Cancers
88. Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma
    Francesca Garofano, Anna Maria Corsale, Marta Biondo · 2026 · Frontiers in Medicine
89. Comparative analysis of three different serum-free light chain assays in the diagnosis of multiple myeloma
    Facai Cui, Jinlin Wang, Xiao Chen · 2026 · Annals of Medicine
90. Clinicopathological features and management of IgM multiple myeloma and Waldenstrom macroglobulinemia
    Shayna Sarosiek, Jorge Julio Castillo, Zachary R. Hunter, Andrew Robert Branagan, Steven Peter Treon · 2026 · Leukemia & lymphoma/Leukemia and lymphoma
91. Ex Vivo Treatment Response Prediction in Multiple Myeloma: Assay Formats, Clinical Correlation, and Future Directions
    Gavin R. Oliver, Carlton C. Barnett, Kendra E. Hightower, Yubin Kang, Muhamed Baljević · 2026 · Cancers
92. Prognostic Significance of SGK1 Expression in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Single‐Center Retrospective Study
    Xiangdong Shen, Haiyan Liu, Xiaoyu Huang · 2026 · Stem Cells International
93. Predicting adverse events for risk stratification of chemotherapy based stem cell mobilization in multiple myeloma
    Friedrich Schwarz, Lena Levien, Markus Maulhardt, Gerald Georg Wulf, Nils Brökers, Enver Aydilek · 2026 · npj Digital Medicine
94. A comprehensive analysis of common cytogenetic abnormalities in multiple myeloma: from basic research to clinical applications.
    Chen-Bo Yang, Xiao-Nan Liu, Yi-Wei Li, Jing-Bo Xiao, Chong-Lin Zhang, Na Zhao, Jiao Shu, Gong-Chang Li, Ting Luo, Kui-Sheng Chen et al. · 2026 · Pathology (Sydney)
95. An oncolytic vaccinia virus encoding CD47 nanobody potentiates antitumor immunity in multiple myeloma
    Lingli Pan, Xiaomeng Zhu, Jiaqing Zhang · 2026 · iScience
96. Efficacy and Safety of Belantamab Mafodotin with Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: The DREAMM-6 Arm B Trial
    Rakesh Popat, Bradley M. Augustson, Paul Cannell, Keith E Stockerl-Goldstein, Andrew G Spencer, Amit S. Khot, Ajay K. Nooka, Nashita Patel, Ravi S. Kasinathan, Astrid McKeown et al. · 2026 · Clinical Cancer Research
97. Autologous Hematopoietic Cell Transplantation (AHCT) for the Treatment of Newly Diagnosed Multiple Myeloma
    Zhubin J. Gahvari, Natalie S. Callander · 2026 · Clinical Lymphoma Myeloma & Leukemia
98. Theranostic Potential of [177Lu]Lu-DOTA-Tocilizumab in Multiple Myeloma: A Preclinical Evaluation
    Ximena Camacho, Mirel Cabrera, Carolina Perroni · 2026 · Anti-Cancer Agents in Medicinal Chemistry
99. Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape
    Francesca Gay, Gabriele Buda, M. T. Petrucci et al. · 2026 · ESMO Open
100. Real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy in inpatient versus outpatient settings
     Murali Janakiram, Lin Fan, Sabyasachi Ghosh et al. · 2026 · Journal of Medical Economics